中华行为医学与脑科学杂志
中華行為醫學與腦科學雜誌
중화행위의학여뇌과학잡지
CHINESE JOURNAL OF BEHAVIORAL MEDICINE AND BRAIN SCIENCE
2010年
12期
1080-1082
,共3页
注射用利培酮微球%非经典抗精神病药物%精神分裂症
註射用利培酮微毬%非經典抗精神病藥物%精神分裂癥
주사용리배동미구%비경전항정신병약물%정신분렬증
Risperidone microsphere injection%Atypical antipsychotic drugs%Schizophrenia
目的 探讨注射用利培酮微球治疗精神分裂症的疗效和安全性.方法 符合诊断标准的82名精神分裂症患者分成2组,分别给予注射用利培酮微球和非经典抗精神病药物利培酮、喹硫平、奥氮平治疗24周.于治疗前及治疗后2,4,12,24周末分别采用阳性与阴性症状量表(PANSS)、个体和社会功能量表(PSP)和副反应量表(TESS)量表评定临床疗效和副反应.结果 2组药物对精神分裂症均有显著疗效,2组治疗后各时间PANSS评分显著低于治疗前[研究组:(44.26±11.41)分,(92.87±12.79)分;对照组:(44.11±10.92)分,(93.35±14.16)分,(P＜0.05)],显效率2组间差异无统计学意义(P＞0.05);注射用利培酮微球治疗组与非经典抗精神病药物治疗组PANSS评定在第4周末差异有统计学意义(P＜0.05),并且在第24周末注射用利培酮微球治疗组得到更好的社会功能恢复(P＜0.05).2组药物的副反应总体差异无统计学意义(P＞0.05);注射用利培酮微球治疗组的静坐不能发生率早期高于口服非经典抗精神病药物组,但差异无统计学意义(P＞0.05);而嗜睡的发生率显著低于口服非经典抗精神病药物(P＜0.05).结论 长效利培酮微球与口服非经典抗精神药物相比疗效相当,社会功能恢复好,副作用较少.
目的 探討註射用利培酮微毬治療精神分裂癥的療效和安全性.方法 符閤診斷標準的82名精神分裂癥患者分成2組,分彆給予註射用利培酮微毬和非經典抗精神病藥物利培酮、喹硫平、奧氮平治療24週.于治療前及治療後2,4,12,24週末分彆採用暘性與陰性癥狀量錶(PANSS)、箇體和社會功能量錶(PSP)和副反應量錶(TESS)量錶評定臨床療效和副反應.結果 2組藥物對精神分裂癥均有顯著療效,2組治療後各時間PANSS評分顯著低于治療前[研究組:(44.26±11.41)分,(92.87±12.79)分;對照組:(44.11±10.92)分,(93.35±14.16)分,(P＜0.05)],顯效率2組間差異無統計學意義(P＞0.05);註射用利培酮微毬治療組與非經典抗精神病藥物治療組PANSS評定在第4週末差異有統計學意義(P＜0.05),併且在第24週末註射用利培酮微毬治療組得到更好的社會功能恢複(P＜0.05).2組藥物的副反應總體差異無統計學意義(P＞0.05);註射用利培酮微毬治療組的靜坐不能髮生率早期高于口服非經典抗精神病藥物組,但差異無統計學意義(P＞0.05);而嗜睡的髮生率顯著低于口服非經典抗精神病藥物(P＜0.05).結論 長效利培酮微毬與口服非經典抗精神藥物相比療效相噹,社會功能恢複好,副作用較少.
목적 탐토주사용리배동미구치료정신분렬증적료효화안전성.방법 부합진단표준적82명정신분렬증환자분성2조,분별급여주사용리배동미구화비경전항정신병약물리배동、규류평、오담평치료24주.우치료전급치료후2,4,12,24주말분별채용양성여음성증상량표(PANSS)、개체화사회공능량표(PSP)화부반응량표(TESS)량표평정림상료효화부반응.결과 2조약물대정신분렬증균유현저료효,2조치료후각시간PANSS평분현저저우치료전[연구조:(44.26±11.41)분,(92.87±12.79)분;대조조:(44.11±10.92)분,(93.35±14.16)분,(P＜0.05)],현효솔2조간차이무통계학의의(P＞0.05);주사용리배동미구치료조여비경전항정신병약물치료조PANSS평정재제4주말차이유통계학의의(P＜0.05),병차재제24주말주사용리배동미구치료조득도경호적사회공능회복(P＜0.05).2조약물적부반응총체차이무통계학의의(P＞0.05);주사용리배동미구치료조적정좌불능발생솔조기고우구복비경전항정신병약물조,단차이무통계학의의(P＞0.05);이기수적발생솔현저저우구복비경전항정신병약물(P＜0.05).결론 장효리배동미구여구복비경전항정신약물상비료효상당,사회공능회복호,부작용교소.
Objective To investigate clinical efficacy and side effects of long-acting risperidone microsphere injection for treatment of patients with schizophrenia. Methods A total of 82 patients with schizophrenia were randomly divided into two groups,study group with long-acting risperidone microsphere injection and control group with atypical antipsychotics treatment for 24 weeks. The Positive and Negative Syndrome Scale (PANSS),The Personal and Social Performance (PSP) and Treatment Emergent Symptoms Scale (TESS) were used to evaluate efficacy and adverse effects of treatment at the end of 1st ,2nd,4th, 12nd and 24th week. Results The therapeutic efficacy in control group was similar to that in study group,and there was no significant difference between the two groups (P＞ 0.05 ). But the therapeutic efficacy in study group was better than that in control group at the end of the 4nd week (P＜0.05 ) , and study group was more likely to improve social function(P ＜ 0. 05 ). Incidence of adverse effects in study group was lower than that in control group , but the difference was not significant (P ＞0.05 ). The incidence of akathisia symptom in study group was higher than that in control group,but the difference was not significant (P＞0.05). The incidence of drowsiness symptom in study group was significantly lower than that in control group(P＜0.05 ). Conclusion Long-acting risperidone microsphere injection is as effective as atypical antipsychotics for treatment of patients with schizophrenia, but it has better efficacy in improving social function of the schizophrenia with lower side effects.
